Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLDX POWR Grades
- CLDX scores best on the Sentiment dimension, with a Sentiment rank ahead of 41.9% of US stocks.
- The strongest trend for CLDX is in Quality, which has been heading down over the past 177 days.
- CLDX's current lowest rank is in the Stability metric (where it is better than 9.52% of US stocks).
CLDX Stock Summary
- CLDX's price/sales ratio is 2,002.4; that's higher than the P/S ratio of 99.76% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.07 for CELLDEX THERAPEUTICS INC; that's greater than it is for merely 7.63% of US stocks.
- Revenue growth over the past 12 months for CELLDEX THERAPEUTICS INC comes in at -86.7%, a number that bests just 1.5% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to CELLDEX THERAPEUTICS INC are FULC, FUSN, CDAK, CEVA, and VLN.
- Visit CLDX's SEC page to see the company's official filings. To visit the company's web site, go to www.celldex.com.
CLDX Valuation Summary
- In comparison to the median Healthcare stock, CLDX's price/earnings ratio is 191.19% lower, now standing at -20.7.
- CLDX's price/sales ratio has moved up 2026.8 over the prior 243 months.
Below are key valuation metrics over time for CLDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLDX | 2023-01-20 | 2036.5 | 6.4 | -20.7 | -20.6 |
| CLDX | 2023-01-19 | 2030.0 | 6.3 | -20.6 | -20.5 |
| CLDX | 2023-01-18 | 2039.1 | 6.4 | -20.7 | -20.6 |
| CLDX | 2023-01-17 | 2050.9 | 6.4 | -20.9 | -20.7 |
| CLDX | 2023-01-13 | 2010.7 | 6.3 | -20.5 | -20.3 |
| CLDX | 2023-01-12 | 2072.3 | 6.5 | -21.1 | -20.9 |
CLDX Growth Metrics
- Its year over year cash and equivalents growth rate is now at -63.51%.
- The 2 year revenue growth rate now stands at -15.07%.
- Its year over year net income to common stockholders growth rate is now at -20.93%.
The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.078 | -96.493 | -105.986 |
| 2022-06-30 | 0.824 | -77.673 | -99.654 |
| 2022-03-31 | 4.141 | -67.359 | -77.023 |
| 2021-12-31 | 4.651 | -60.909 | -70.511 |
| 2021-09-30 | 8.103 | -51.597 | -72.263 |
| 2021-06-30 | 8.618 | -47.086 | -66.035 |
CLDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLDX has a Quality Grade of D, ranking ahead of 19.92% of graded US stocks.
- CLDX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
- CALA, CYRX, and BDSI are the stocks whose asset turnover ratios are most correlated with CLDX.
The table below shows CLDX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.038 | 1 | -0.480 |
| 2021-03-31 | 0.022 | 1 | -0.447 |
| 2020-12-31 | 0.034 | 1 | -0.479 |
| 2020-09-30 | 0.024 | 1 | -0.470 |
| 2020-06-30 | 0.028 | 1 | -0.636 |
| 2020-03-31 | 0.038 | 1 | -0.864 |
CLDX Price Target
For more insight on analysts targets of CLDX, see our CLDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $64.83 | Average Broker Recommendation | 1.25 (Strong Buy) |
CLDX Stock Price Chart Interactive Chart >
CLDX Price/Volume Stats
| Current price | $46.25 | 52-week high | $48.40 |
| Prev. close | $45.83 | 52-week low | $19.85 |
| Day low | $45.37 | Volume | 225,500 |
| Day high | $46.94 | Avg. volume | 390,939 |
| 50-day MA | $41.30 | Dividend yield | N/A |
| 200-day MA | $32.93 | Market Cap | 2.18B |
Celldex Therapeutics Inc. (CLDX) Company Bio
Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.
Latest CLDX News From Around the Web
Below are the latest news stories about CELLDEX THERAPEUTICS INC that investors may wish to consider to help them evaluate CLDX as an investment opportunity.
As Celldex Recovers, Here's My StrategyCelldex Therapeutics is a clinical stage biotechnology company that is developing therapies for types of inflammatory, autoimmune and cancer-related diseases. Let's check out the charts. In this daily bar chart of CLDX, below, I see a strong rally from June. |
What Analysts Were Expecting After Celldex Therapeutics Inc. (NASDAQ: CLDX) fell -1.04%Celldex Therapeutics Inc. (NASDAQ:CLDX) shares, rose in value on Friday, 12/30/22, with the stock price down by -1.04% to the previous day’s close as strong demand from buyers drove the stock to $44.57. Actively observing the price movement in the last trading, the stock closed the session at $45.04, falling within a range of $43.81 … What Analysts Were Expecting After Celldex Therapeutics Inc. (NASDAQ: CLDX) fell -1.04% Read More » |
Celldex Therapeutics Inc. (CLDX) can beat the pack with these strategiesA share of Celldex Therapeutics Inc. (NASDAQ:CLDX) closed at $45.04 per share on Thursday, up from $43.19 day before. While Celldex Therapeutics Inc. has overperformed by 4.28%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLDX rose by 15.22%, with highs and lows ranging from $45.65 […] |
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients - - Long term follow up of patients with chronic inducible urticaria treated at 3.0 mg/kg confirm that barzolvolimab-induced responses and mast cell suppression are durable and linked - - Company to host webcast conference call on Tuesday, December 6 at 8:00 a.m. ET - |
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022- Includes oral presentation for 1.5 mg/kg cold urticaria cohort - - Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET - HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th |
CLDX Price Returns
| 1-mo | 3.77% |
| 3-mo | 31.65% |
| 6-mo | 53.15% |
| 1-year | 59.37% |
| 3-year | 1,902.16% |
| 5-year | 10.12% |
| YTD | 3.77% |
| 2022 | 15.35% |
| 2021 | 120.55% |
| 2020 | 685.65% |
| 2019 | -25.67% |
| 2018 | -92.96% |
Continue Researching CLDX
Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...